Company Overview
NeuroSense Therapeutics Ltd. operates as a clinical-stage biotechnology entity dedicated to the discovery and development of therapeutic treatments for patients suffering from debilitating neurodegenerative diseases within the United States and international markets. The company's primary focus is centered on its lead product, PrimeC, which is an extended-release oral formulation designed to address specific neurological conditions. This biotechnology firm functions within the healthcare sector, specifically the biotechnology industry, where innovation in drug discovery is critical for advancing patient outcomes. As of the latest data, the company maintains a market capitalization of $24.41M and employs a workforce of 17 individuals. The relatively small market cap combined with the absence of reported annual revenue indicates that NeuroSense is in an early-stage development phase typical for clinical-stage biotechnology companies, where value is derived from pipeline potential rather than established commercial sales streams.
Financial Health
The company reports a net income of $-8,658,000 over the trailing twelve months, while revenue figures are not available for reporting, resulting in a profit margin of 0.0%. The gap between the reported net income loss and the EBITDA of $-8,551,000 reveals a significant cost structure dominated by non-operating expenses or specific financial charges that impact the bottom line more severely than operating earnings. Free cash flow stands at $-6,569,250, indicating that the company is consuming cash reserves to fund its research and development activities, which limits immediate financial flexibility until product commercialization occurs. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting the nature of a clinical-stage company that has not yet generated sufficient sales to establish positive profitability or coverage ratios. The balance sheet shows a cash position of $666,000 with no reported debt figures, suggesting the company relies entirely on equity financing and internal reserves to sustain operations. With a current ratio of 0.71, the company's short-term liquidity is constrained, as current liabilities exceed current assets, signaling a potential need for additional capital or refinancing in the near term. Return on equity and return on assets metrics are not available due to the lack of positive earnings, though the return on assets is calculated at -303.9%, which highlights the extent of losses relative to the asset base.
Valuation Assessment
The valuation metrics present a complex picture, with a forward P/E ratio of -4.06 and a trailing P/E ratio listed as N/A, implying that the company has not yet achieved positive earnings required for standard profitability valuation models. The price-to-book ratio is recorded at -34.81, a negative figure that indicates the market capitalization is less than the book value of equity, often seen in speculative biotechnology assets with no current revenue. Alternative valuation metrics such as the price-to-sales ratio are listed as N/A, while the EV/EBITDA stands at -2.02, further confirming that traditional earnings-based valuation methods are not applicable at this stage of the company's lifecycle. The stock has exhibited significant price volatility over the past year, with a 52-week high of $2.60 and a 52-week low of $0.68. Without the current share price explicitly provided in the source data to calculate the exact percentage difference, the trading range defines the maximum historical premium and discount experienced by the security relative to its recent lows. The beta value is 1.61, which signifies that the stock price is expected to be 61% more volatile than the broader market index, reflecting the high risk associated with clinical-stage biotechnology investments.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet generated revenue sufficient to calculate meaningful growth rates. Since earnings growth cannot be compared to revenue growth due to the absence of revenue data, the implication is that the company is in a pre-revenue stage where growth is measured by pipeline milestones rather than financial statements. As a non-dividend payer, the company does not distribute a dividend yield, which is listed as N/A, nor does it have a payout ratio, recorded as 0.0%. This financial profile indicates that the company retains all available resources, including its cash balance, to reinvest directly into research and development efforts rather than returning capital to shareholders. The overall growth and income profile is characterized by a complete reliance on future clinical success and potential regulatory approvals to transition from a cash-burning entity to a revenue-generating business.